Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics

Documenti analoghi

• Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines
  di: Richard Furie, et al.
  Pubblicazione: (2025)
• Expert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy
  di: Jacqueline A. Madison, et al.
  Pubblicazione: (2025)
• Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis
  di: Stefano Di Donato, et al.
  Pubblicazione: (2025)
• Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus
  di: Takehiro Hirayama, et al.
  Pubblicazione: (2026)
• Reply
  di: Shae Chambers, et al.
  Pubblicazione: (2026)